JP6538682B2 - Ｃｇｒｐアゴニストペプチド - Google Patents

Ｃｇｒｐアゴニストペプチド Download PDF

Info

Publication number
JP6538682B2
JP6538682B2 JP2016531836A JP2016531836A JP6538682B2 JP 6538682 B2 JP6538682 B2 JP 6538682B2 JP 2016531836 A JP2016531836 A JP 2016531836A JP 2016531836 A JP2016531836 A JP 2016531836A JP 6538682 B2 JP6538682 B2 JP 6538682B2
Authority
JP
Japan
Prior art keywords
cgrp
agonist
peptide
seq
related peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016531836A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016528231A5 (https=
JP2016528231A (ja
Inventor
ソアレス、クリストファー、ジェイ．
Original Assignee
ソアレス クリストファー ジェイ．
ソアレス クリストファー ジェイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ソアレス クリストファー ジェイ．, ソアレス クリストファー ジェイ． filed Critical ソアレス クリストファー ジェイ．
Publication of JP2016528231A publication Critical patent/JP2016528231A/ja
Publication of JP2016528231A5 publication Critical patent/JP2016528231A5/ja
Application granted granted Critical
Publication of JP6538682B2 publication Critical patent/JP6538682B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57527—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2016531836A 2013-07-30 2014-07-29 Ｃｇｒｐアゴニストペプチド Active JP6538682B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361860244P 2013-07-30 2013-07-30
US61/860,244 2013-07-30
PCT/US2014/048724 WO2015017455A1 (en) 2013-07-30 2014-07-29 Cgrp agonist peptides

Publications (3)

Publication Number Publication Date
JP2016528231A JP2016528231A (ja) 2016-09-15
JP2016528231A5 JP2016528231A5 (https=) 2017-09-07
JP6538682B2 true JP6538682B2 (ja) 2019-07-03

Family

ID=51355665

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016531836A Active JP6538682B2 (ja) 2013-07-30 2014-07-29 Ｃｇｒｐアゴニストペプチド

Country Status (4)

Country Link
US (1) US9951115B2 (https=)
EP (1) EP3027644B1 (https=)
JP (1) JP6538682B2 (https=)
WO (1) WO2015017455A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10464983B2 (en) 2015-05-13 2019-11-05 The Board Of Regents Of The University Of Oklahoma Variants of adrenomedullin and calcitonin gene-related peptide and methods of use
EP3366286A1 (en) * 2017-02-22 2018-08-29 Johannes Keller Compounds for treating sepsis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021665A1 (en) * 1993-03-24 1994-09-29 Amylin Pharmaceuticals, Inc. Cloned receptors and methods for screening
RU2385878C2 (ru) * 2004-02-11 2010-04-10 Амилин Фармасьютикалз, Инк. Пептид, обладающий свойствами амилина (варианты), и его применение (варианты)
EP2286840A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related diseases
EP2258382A3 (en) * 2005-03-31 2014-05-14 Amylin Pharmaceuticals, LLC Amylin and amylin agonists for treating psychiatric diseases and disorders
WO2007055743A2 (en) 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
KR20100098628A (ko) * 2007-11-14 2010-09-08 아밀린 파마슈티칼스, 인크. 비만 및 비만 관련 질환 및 장애의 치료 방법
US8748375B2 (en) * 2009-03-17 2014-06-10 Amylin Pharmaceuticals, Llc Methods for affecting body composition using amylin agonists
US20140249076A1 (en) * 2011-10-18 2014-09-04 Astrazeneca Pharmaceuticals Lp Amylin-calcitonin chimeric peptides conjugated to duration enhancing moieties
CA2861392C (en) * 2012-01-26 2021-08-17 Christopher J. Soares Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use

Also Published As

Publication number Publication date
JP2016528231A (ja) 2016-09-15
EP3027644A1 (en) 2016-06-08
US9951115B2 (en) 2018-04-24
WO2015017455A1 (en) 2015-02-05
EP3027644B1 (en) 2019-08-21
US20160207975A1 (en) 2016-07-21

Similar Documents

Publication Publication Date Title
KR102351313B1 (ko) Gip/glp1 공효능제 화합물
JP6247205B2 (ja) ポリペプチド
CN102918055B (zh) 新的胰高血糖素类似物
EP2152297B1 (en) Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
RU2742826C2 (ru) Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение
RS60432B1 (sr) Upotreba glp-1 peptida sa dugim dejstvom
CN104395338A (zh) 人胰岛淀粉样多肽类似物
JP2016519130A (ja) 治療ペプチド
EP2340261A1 (en) Amylin derivatives
ZA200705168B (en) Y2/Y4 selective receptor agonists for therapeutic interventions
AU2005224026A1 (en) Y2 selective receptor agonists for therapeutic interventions
US8318664B2 (en) Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity
JP2010505404A (ja) プロラクチンレセプターに対して高親和性を有するペプチド
JP6538682B2 (ja) Ｃｇｒｐアゴニストペプチド
CN120981479A (zh) Gip/glp1/gcg三受体激动剂及其用途
CN117186189A (zh) 一种兼具降糖和减重作用的glp-1/cck-1受体双重激动多肽及其应用
TW200829266A (en) Peptides with high affinity for the prolactin receptor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160330

A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20160329

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20160729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180718

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190606

R150 Certificate of patent or registration of utility model

Ref document number: 6538682

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250